David Williams

We strongly encourage D&E trainees to complete this survey developed by the SAC, ABCD and SfE to evaluate GIM commitment during training and support improving this aspect of training. forms.cloud.microsoft/e/HASvMueAXk

Great workshops on the role of dietitians and psychologists in tier 3 and tier 4 weight management services, as well as in the impact bariatric surgery Mary O’Kane @Mpmok , Dr Mark Loveder, Mr Andrew Beemish @beamishaj

This marks the end of our 2-day obesity course, thank you to all participants and speakers for your support including Dr Jodi Wood, Professor Dan Cuthbertson and Dr Anna Stears

Excellent talks on running a tier 3 weight management service, pharmacotherapies for obesity and lipid disorders yesterday by Dr David Hughes & Dr Faizanur Rahman

Great start to the first day of our Obesity Course in Nottingham! @DrDavidMW , Dr Anjali Zalin, @BrocqSarah

The Obesity, Metabolism and Lipids course is taking place at Nottingham Jubilee Centre, July 7-8th. One night accommodation is included. Registration and further information are available using the following link: redhotirons.com/ydef-obesity-m…

Members of the YDEF committee at the #DUKPC25! A week of learning about incredible advances in diabetes care! We are looking forward to the #sfebes2025 conference in a couple of weeks! @ABCDiab @Soc_Endo @DiabetesUK

It’s great to be starting @DiabetesUKProf #DUKPC2025 week with the YDEF Day @youngdiabendo!

Thank you to all the speakers for their excellent talks at YDEF Day 2025! Topics included an update on neuroendocrine tumours, adolescent T2D and managing diabetes technology for inpatients. There's still more to come on screening and immunoprevention of T1D! @youngdiabendo

🚀 Calling early-career diabetologists! The North European Young Diabetologists (NEYD) 2025 is your chance to present research to peers and world-renowned academics. Submit your abstract by 23 February 🔗 docs.google.com/forms/d/e/1FAI… @youngdiabendo

The FASCINATE-2 trial: The effects of fatty acid synthase inhibitor #denifanstat targeting de-novo lipogenesis pathways to treat #MASLD. thelancet.com/journals/langa…

Excellent review on steatotic liver disease. #MASLD #MASH @AleksanderKrag pubmed.ncbi.nlm.nih.gov/39488409/

8th SCE Endocrinology Course: Dates: July 4th- 6th, 2025. (Friday 2 pm onwards- Sunday) Venue: Lecture theatre, Royal Glamorgan Hospital, Llantrisant CF72 8XR Please save the dates; details to follow. @drpunith @ahmed_alsharefi @DrIshratKhan @Melanie_Nana1 @welshendodiab

**YDEF Day registration is open!** Join us on Tues 25th Feb 2025 in Glasgow, to learn about hot topics in endocrinology and diabetes, plus presentations from those shortlisted for our Marjorie prize. Well suited to all training grades. Register dukpc2025.eventreference.com/content.php?sc…

Top 2024 Article: Natural history and progression of metabolic dysfunction-associated steatotic liver disease. thelancet.com/journals/langa…

People with diabetes tend to lose less weight with GLP-1 analogues, but those with MASLD/MASH have similar weight loss with semaglutide regardless of type 2 diabetes status. #MASH #MASH …ubs.pericles-prod.literatumonline.com/doi/10.1111/do…

A comprehensive review of navigating liver health with #metabolomics. #MASLD #MASH pubmed.ncbi.nlm.nih.gov/39536895/

Approximately 38% of the global population has metabolic dysfunction-associated steatotic liver disease (MASLD). A @TheLancetEndo Review explores the differences in causes of MASLD, risk prediction & how patients respond to metabolism-based treatments: hubs.li/Q0300Pym0

ADA Standards of Care in Diabetes—2025: #MASLD treatment algorithm. @ADA_DiabetesPro diabetesjournals.org/care/article/4…

New—Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment thelancet.com/journals/landi… #MASLD #OpenAccess